Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$3.2 million.

  • Anika Therapeutics' Income from Continuing Operations fell 6933.33% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year decrease of 25909.09%. This contributed to the annual value of -$10.1 million for FY2024, which is 19491.13% down from last year.
  • As of Q3 2025, Anika Therapeutics' Income from Continuing Operations stood at -$3.2 million, which was down 6933.33% from -$4.7 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Income from Continuing Operations high stood at $16.2 million for Q4 2023, and its period low was -$10.3 million during Q1 2023.
  • Over the past 5 years, Anika Therapeutics' median Income from Continuing Operations value was -$2.8 million (recorded in 2022), while the average stood at -$976263.2.
  • Within the past 5 years, the most significant YoY rise in Anika Therapeutics' Income from Continuing Operations was 41137.91% (2022), while the steepest drop was 85398.55% (2022).
  • Anika Therapeutics' Income from Continuing Operations (Quarter) stood at -$3.2 million in 2021, then soared by 411.38% to $10.1 million in 2022, then soared by 60.71% to $16.2 million in 2023, then tumbled by 123.48% to -$3.8 million in 2024, then rose by 16.45% to -$3.2 million in 2025.
  • Its Income from Continuing Operations was -$3.2 million in Q3 2025, compared to -$4.7 million in Q2 2025 and -$4.0 million in Q1 2025.